OncoMatch/Clinical Trials/NCT06905587
Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue
Is NCT06905587 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Methylphenidate (MPH) for brain tumor, pediatric.
Treatment: Methylphenidate (MPH) — Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking. The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD). If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: treatment for pediatric brain tumor
Treated for a PBT during the previous 10 years, starting from date of diagnosis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify